EUVIMEDEUVIMED entdecken
Crossref

Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders

Santosh Kumar Rai iD, Rakesh Ishwar Patil, Sazid Ali, Rakesh Kumar, Mohd Imran Khan, Amit Panwar, Srinivasa Reddy, Muneeb Ahsan, Sunil Iyer, Anil Kumar

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00540 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Santosh Kumar Rai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mankind Research Centre, Mankind Pharma Limited, Gurugram 122051, India. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Metabolic Diseases, Drug Discovery, Small Molecule Libraries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GPR119 modulation is reported to have a promising role for preventing or managing various metabolic disorders, including type 2 diabetes, insulin resistance, loss of beta cell function, hyperlipidemia, obesity, fatty liver, MASH, and cirrhosis. We have developed a potent GPR119 agonist, MKP10241, which has elevated cyclic adenosine monophosphate (cAMP) levels in the GPR119 expressing cell line and reduced blood glucose levels and HbA1c in acute models and a chronic diabetic mouse model. Chronic treatment of MKP10241 in DIO-mice exhibited marked reduction in body weight and feed intake at tested doses, which was associated with decreased blood glucose level, lipid parameters, and body fats. Further evaluation of MKP10241 in the STAM mouse model of MASH/MASLD showed significant MASH resolution. MKP10241 was evaluated in preclinical toxicity and genotoxicity studies in rats and dogs and found safe. Considering the preclinical safety and efficacy profile, MKP10241 has been advanced for safety, tolerability, and pharmacokinetic evaluation in healthy volunteers in a Phase-I clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledMetabolic DiseasesDrug DiscoverySmall Molecule LibrariesAnimalsHumansMiceRatsDogsMaleStructure-Activity RelationshipDiabetes Mellitus, ExperimentalBlood GlucoseCyclic AMP

Substanzen

Receptors, G-Protein-CoupledGPR119 protein, humanSmall Molecule LibrariesBlood GlucoseCyclic AMP

Autor:innen und Institutionen

  • Mankind Research Centre, Mankind Pharma Limited, Gurugram 122051, India.

ORCID-Profile: Santosh Kumar Rai

Zitieren

APA

Rai, S. K., Patil, R. I., Ali, S., Kumar, R., Khan, M. I., Panwar, A., Reddy, S., Ahsan, M., Iyer, S., & Kumar, A. (2025). Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00540

Vancouver

Rai SK, Patil RI, Ali S, Kumar R, Khan MI, Panwar A, et al. Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00540

BibTeX
@article{Rai2025,
  author = {Rai, Santosh Kumar and Patil, Rakesh Ishwar and Ali, Sazid and Kumar, Rakesh and Khan, Mohd Imran and Panwar, Amit and Reddy, Srinivasa and Ahsan, Muneeb and Iyer, Sunil and Kumar, Anil},
  title = {Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00540}
}
Kostenlos starten →